ICT

Shanghai Si Dan Race BioTechnology Co., Ltd. (ICT) is a company focused on the development of innovative CAR-T cell therapies for the treatment of hematologic malignancies and solid tumors. ICT has already achieved outstanding preclinical and clinical results using cutting-edge CAR-T technology in diseases such as advanced lymphoma and leukemia. This year, ICT's product ICTCAR014, which targets NHL with CD19 and expresses Dominant Negative PD-1, received FDA approval for clinical trials in the United States. Previously, its CD19-targeting product for B-cell acute lymphoblastic leukemia received clinical trial approval from China's Center for Drug Evaluation. Shanghai Si Dan Race BioTechnology Co., Ltd. (ICT) has a rich pipeline of solid tumor products, with multiple innovative CAR-T technologies currently under development and in clinical trials.